Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1191-1198

  Guilhaumou, Romain ^a,b   Simon, Nicolas ^b   Quaranta, Sylvie ^b   Verschuur, Arnauld ^b   Lacarelle, Bruno ^a,b   Andre, Nicolas ^a,b   Solas, Caroline ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

Paediatric; Pharmacogenetics; Population pharmacokinetics; Solid tumours; Vincristine

Indexed keywords

TEVA; UNCLASSIFIED DRUG; VINCRISTINE;

ABCB1 GENE; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOCHROME P450 3A4 GENE; CYTOCHROME P450 3A5 GENE; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE SEQUENCE; GENOTYPE; HAPLOTYPE; HUMAN; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; NEUROTOXICITY; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; SOLID TUMOR; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOCHROME P-450 CYP3A; FEMALE; HAPLOTYPES; HUMANS; MALE; NEOPLASMS; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; VINCRISTINE;

EID: 82455175261     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1541-4     Document Type: Article

References (32)

1. CE Gidding GJ Meeuwsen-de Boer P Koopmans DR Uges WA Kamps SS de Graaf 1999 Vincristine pharmacokinetics after repetitive dosing in children Cancer Chemother Pharmacol 44 203 209 10453721 10.1007/s002800050968 1:CAS:528:DyaK1MXkvVyhsL0%3D (Pubitemid 29350175)
2. G Lönnerholm BM Frost J Abrahamsson M Behrendtz A Castor E Forestier M Heyman DR Uges SS de Graaf 2008 Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia Br J Haematol 142 616 621 18537965 10.1111/j.1365-2141.2008.07235.x (Pubitemid 352020218)
3. E Groninger T Meeuwsen-de Boer P Koopmans D Uges W Sluiter A Veerman W Kamps S de Graaf 2005 Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch childhood leukaemia study group (DCLSG) Eur J Cancer 41 98 103 15617994 10.1016/j.ejca.2004.10.006 1:CAS:528:DC%2BD2MXhtVGjuw%3D%3D (Pubitemid 40029662)
4. R Rahmani XJ Zhou 1993 Pharmacokinetics and metabolism of vinca alkaloids Cancer Surv 17 269 281 8137344 1:CAS:528:DyaK2cXktVSjuro%3D
5. JB Dennison P Kulanthaivel RJ Barbuch JL Renbarger WJ Ehlhardt SD Hall 2006 Selective metabolism of vincristine in vitro by CYP3A5 Drug Metab Dispos 34 1317 1327 16679390 10.1124/dmd.106.009902 1:CAS:528:DC%2BD28Xnslakur0%3D (Pubitemid 44079872)
6. A Böhme A Ganser D Hoelzer 1995 Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL Ann Hematol 71 311 312 8534764 10.1007/BF01697985 (Pubitemid 26002070)
7. M Kamaluddin P McNally F Breatnach A O'Marcaigh D Webb E O'Dell P Scanlon K Butler A O'Meara 2001 Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies Acta Paediatr 90 1204 1207 11697438 10.1111/j.1651-2227.2001.tb03257.x 1:STN:280:DC%2BD3MnksFSjsA%3D%3D (Pubitemid 32964502)
8. RK Sathiapalan H El-Solh 2001 Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature Pediatr Hematol Oncol 18 543 546 11764105 10.1080/088800101753328529 1:STN:280:DC%2BD38%2FjslKqtw%3D%3D (Pubitemid 33110932)
9. RH van Schaik 2008 CYP450 pharmacogenetics for personalizing cancer therapy Drug Resist Updat 11 77 98 18486526 10.1016/j.drup.2008.03.002
10. BH Pollock MR DeBaun BM Camitta JJ Shuster Y Ravindranath DJ Pullen VJ Land DH Mahoney Jr SJ Lauer SB Murphy 2000 Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a pediatric oncology group study J Clin Oncol 18 813 823 10673523 1:STN:280:DC%2BD3c7jvFCrtA%3D%3D (Pubitemid 30106612)
11. JL Renbarger KC McCammack CE Rouse SD Hall 2008 Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients Pediatr Blood Cancer 50 769 771 18085684 10.1002/pbc.21435 (Pubitemid 351354782)
12. JB Dennison DR Jones JL Renbarger SD Hall 2007 Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes J Pharmacol Exp Ther 321 553 563 17272675 10.1124/jpet.106.118471 1:CAS:528: DC%2BD2sXltFehtb0%3D (Pubitemid 46628594)
13. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169-174. Erratum in: Clin Pharmacol Ther (2004) 75:124 (Pubitemid 32225417)
14. M Tanabe I Ieiri N Nagata K Inoue S Ito Y Kanamori M Takahashi Y Kurata J Kigawa S Higuchi N Terakawa K Otsubo 2001 Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene J Pharmacol Exp Ther 297 1137 1143 11356939 1:CAS:528:DC%2BD3MXjvVShs7k%3D (Pubitemid 32472514)
15. FC Chou SJ Tzeng JD Huang 2001 Genetic polymorphism of cytochrome P450 3A5 in Chinese Drug Metab Dispos 29 1205 1209 11502729 1:CAS:528: DC%2BD3MXmt1Whurk%3D
16. E Coto B Tavira 2009 Pharmacogenetics of calcineurin inhibitors in renal transplantation Transplantation 15 62 67 10.1097/TP.0b013e3181afe9e7
17. R Guilhaumou C Solas A Rome M Giocanti N Andre B Lacarelle 2010 Validation of an electrospray ionization LC/MS/MS method for quantitative analysis of vincristine in human plasma samples J Chromatogr B Analyt Technol Biomed Life Sci 878 423 427 20042378 10.1016/j.jchromb.2009.12.015 1:CAS:528:DC%2BC3cXotlWisQ%3D%3D
18. S Quaranta D Chevalier V Bourgarel-Rey D Allorge C Solas JM Lo-Guidice E Sampol-Manos H Vacher-Coponat V Moal F Broly M Lhermitte B Lacarelle 2006 Identification by single-strand conformational polymorphism analysis of known and new mutations of the CYP3A5 gene in a French population Toxicol Lett 164 177 184 16442753 10.1016/j.toxlet.2005.12.007 1:CAS:528:DC%2BD28XksVCqs7k%3D
19. M Stephens NJ Smith P Donnelly 2001 A new statistical method for haplotype reconstruction from population data Am J Hum Genet 68 978 989 11254454 10.1086/319501 1:STN:280:DC%2BD3M3kslWgsA%3D%3D (Pubitemid 32289743)
20. Beal S, Sheiner LB (1991) NONMEM user's guide. NONMEM project group, University of California, San Francisco
21. Boeckmann A, Sheiner L, Beal S (1994) NONMEM user's guide-part V. NONMEM project group, University of California, San Francisco
22. MO Karlsson EN Jonsson CG Wiltse JR Wade 1998 Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients J Pharmacokinet Biopharm 26 207 246 9795882 10.1023/A:1020561807903 1:CAS:528:DyaK1cXntVKqurY%3D (Pubitemid 28496599)
23. S Hoffmeyer O Burk O von Richter HP Arnold J Brockmöller A Johne I Cascorbi T Gerloff I Roots M Eichelbaum U Brinkmann 2000 Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 97 3473 3478 10716719 10.1073/pnas.050585397 1:CAS:528:DC%2BD3cXitlWqtL8%3D (Pubitemid 30183327)
24. A Moore R Pinkerton 2009 Vincristine: can its therapeutic index be enhanced? Pediatr Blood Cancer 53 1180 1187 19588521 10.1002/pbc.22161 Review
25. VS Sethi JC Kimball 1981 Pharmacokinetics of vincristine sulfate in children Cancer Chemother Pharmacol 6 2 111 115 7307229 10.1007/BF00262326 1:STN:280:DyaL38%2FntVKgtg%3D%3D (Pubitemid 12237908)
26. SJ Kellie P Koopmans J Earl C Nath D Roebuck DR Uges SS De Graaf 2004 Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors Cancer 100 2637 2643 15197807 10.1002/cncr.20220 1:CAS:528:DC%2BD2cXlsFChs7g%3D (Pubitemid 38715770)
27. E Groninger T Meeuwsen-de Boar P Koopmans D Uges W Sluiter A Veerman W Kamps S de Graaf 2002 Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia Pediatr Res 52 113 118 12084857 10.1203/00006450-200207000-00021 1:CAS:528:DC%2BD38XlvFWnuro%3D (Pubitemid 34665960)
28. HW Van den Berg ZR Desai R Wilson G Kennedy JM Bridges RG Shanks 1982 The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination Cancer Chemother Pharmacol 8 215 219 7105384 10.1007/BF00255487 (Pubitemid 12081392)
29. BM Frost G Lönnerholm P Koopmans J Abrahamsson M Behrendtz A Castor E Forestier DR Uges SS de Graaf 2003 Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents Acta Paediatr 92 551 557 12839283 10.1111/j.1651-2227.2003.tb02505.x 1:STN:280: DC%2BD3szhtVyqtg%3D%3D (Pubitemid 37088699)
30. M Dumas C de Gislain P d'Athis V Chadoint-Noudeau A Escousse J Guerrin N Autissier 1990 Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II) Cancer Chemother Pharmacol 26 278 282 2369792 10.1007/BF02897230 1:STN:280: DyaK3czhsFOiug%3D%3D (Pubitemid 20211114)
31. SL Plasschaert E Groninger M Boezen I Kema EG de Vries D Uges AJ Veerman WA Kamps E Vellenga SS de Graaf ES de Bont 2004 Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia Clin Pharmacol Ther 76 3 220 229 15371983 10.1016/j.clpt.2004.05.007 1:CAS:528:DC%2BD2cXnslKks7k%3D (Pubitemid 39221796)
32. A Hartman RH van Schaik IP van der Heiden MJ Broekhuis M Meier ML den Boer R Pieters 2010 Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia Leuk Res 34 2 154 159 19467705 10.1016/j.leukres.2009.04.027 1:CAS:528:DC%2BC3cXhtlGgt70%3D